0452 GMT - CSL still generates caution at Macquarie despite the stock's recent rerate. Analysts at the investment bank keep a neutral rating on the Australia-based pharmaceutical company, observing that a 58% share-price rise over three months came despite earnings downgrades. They think that near-term catalysts will probably support the current rerating, but tell clients in a note that they are cautious on the medium-term outlook due to uncertainty over the impact on demand of complement-inhibitor therapies, albumin collections, and the process to appoint a new permanent CEO. Macquarie raises its target price on the stock 31% to 174.00 Australian dollars. Shares are up 1.4% at A$184.25.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.